Case number 1:23-cv-01264
Takeda Pharmaceuticals U.S.A., Inc. v. Scilex Pharmaceuticals Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 3, 2024 | 20 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,619,004; 7,820,681; 7,964,648; 8,093,297; 8,097,655; 8,440,722. (Attachments: # 1 Consent Judgment and Order of Permanent Injunction)(nms) (Entered: 05/03/2024) (0) |
| May 3, 2024 | 19 | CONSENT JUDGMENT and Order of Permanent Injunction. Signed by Judge Richard G. Andrews on 5/3/2024. (nms) (Entered: 05/03/2024) (4) |
| May 3, 2024 | 18 | PROPOSED Consent Judgment and Order of Permanent Injunction, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 5/3/2024 (nms). (Entered: 05/03/2024) (4) |
| Mar 18, 2024 | 17 | SO ORDERED Granting 16 Stipulation and Proposed Order to Stay Action Pending Regulatory Review of Settlement. Signed by Judge Richard G. Andrews on 3/18/2024. (nms) (Entered: 03/18/2024) (2) |
| Mar 18, 2024 | 16 | STIPULATION To Stay Action Pending Regulatory Review of Settlement by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 03/18/2024) (2) |
| Feb 6, 2024 | N/A | Pro Hac Vice Attorney Joseph M. Reisman for Scilex Holding Company and Scilex Pharmaceuticals Inc., added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 02/06/2024) (0) |
| Feb 6, 2024 | N/A | Pro Hac Vice Attorney Ashley C. Morales for Scilex Holding Company and Scilex Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/06/2024) (0) |
| Feb 5, 2024 | N/A | Pro Hac Vice Attorney William R. Zimmerman for Scilex Holding Company and Scilex Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/05/2024) (0) |
| Feb 5, 2024 | N/A | SO ORDERED, re 14 MOTION for Pro Hac Vice Appearance of Attorney Joseph M. Reisman, William R. Zimmerman and Ashley C. Morales, filed by Scilex Holding Company, Scilex Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/5/2024. (nms) (Entered: 02/05/2024) (0) |
| Feb 5, 2024 | 15 | Pro Hac Vice Fee - Credit Card Payment received for Joseph M. Reisman, William R. Zimmerman, and Ashley C. Morales. ( re 14 MOTION for Pro Hac Vice Appearance of Attorney Joseph M. Reisman, William R. Zimmerman and Ashley C. Morales )( Payment of $ 150, receipt number ADEDC-4330296).(Haney, Megan) (Entered: 02/05/2024) (0) |
| Feb 5, 2024 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Joseph M. Reisman, William R. Zimmerman and Ashley C. Morales - filed by Scilex Holding Company, Scilex Pharmaceuticals Inc.. (Attachments: # 1 Certification of Joseph M. Reisman, # 2 Certification of Willam R. Zimmerman, # 3 Certification of Ashley C. Morales)(Haney, Megan) (Entered: 02/05/2024) (0) |
| Feb 1, 2024 | 13 | NOTICE of Appearance by Megan C. Haney on behalf of Scilex Holding Company, Scilex Pharmaceuticals Inc. (Haney, Megan) (Entered: 02/01/2024) (1) |
| Jan 30, 2024 | N/A | SO ORDERED, re 12 Stipulation and Order Regarding Response to Complaint and Waiver of Service of Process (*Reset Answer Deadlines: Scilex Holding Company answer due 3/29/2024; Scilex Pharmaceuticals Inc. answer due 3/29/2024). Signed by Judge Richard G. Andrews on 1/30/2024. (nms) (Entered: 01/30/2024) (0) |
| Jan 30, 2024 | 12 | STIPULATION and Order Regarding Response to Complaint and Waiver of Service of Process, by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 1/30/2024 (nms). (Entered: 01/30/2024) (2) |
| Nov 29, 2023 | N/A | Pro Hac Vice Attorneys Porter F. Fleming and Edgar H. Haug for Takeda Pharmaceuticals U.S.A., Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 11/29/2023) (0) |
| Nov 28, 2023 | N/A | SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug and Porter F. Fleming, filed by Takeda Pharmaceuticals U.S.A., Inc.. Signed by Judge Richard G. Andrews on 11/28/2023. (nms) (Entered: 11/28/2023) (0) |
| Nov 28, 2023 | 11 | MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug and Porter F. Fleming - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 11/28/2023) (3) |
| Nov 21, 2023 | 10 | REDACTED VERSION of 3 Complaint, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibits A-K, # 2 Exhibit L, # 3 Civil Cover Sheet)(DiGiovanni, Francis) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (0) |
| Nov 14, 2023 | 9 | ORAL ORDER: The redacted filing (D.I. 8 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 11/14/2023. (nms) (Entered: 11/14/2023) (0) |
| Nov 13, 2023 | 8 | REDACTED VERSION of 3 Complaint, by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Civil Cover Sheet, # 2 Exhibits A-K, # 3 Exhibit L)(DiGiovanni, Francis) (Entered: 11/13/2023) (0) |
| Nov 8, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 11/08/2023) (0) |
| Nov 7, 2023 | N/A | Remark: Case submitted for routine judicial assignment (jfm) (Entered: 11/07/2023) (0) |
| Nov 7, 2023 | 7 | ORDER Granting 1 MOTION for Confidential Treatment of the Complaint and its Exhibit L. Signed by Judge Richard G. Andrews on 11/7/2023. (nms) (Entered: 11/07/2023) (1) |
| Nov 6, 2023 | N/A | Remark:Exit electronic copies to Judge RGA (jfm) (Entered: 11/06/2023) (0) |
| Nov 6, 2023 | N/A | No Summons Issued. (jfm) (Entered: 11/06/2023) (0) |
| Nov 6, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (jfm) (Entered: 11/06/2023) (2) |
| Nov 6, 2023 | 5 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) see attached. (jfm) (Entered: 11/06/2023) (1) |
| Nov 6, 2023 | 4 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: September 25, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/25/2026. (jfm) (Entered: 11/06/2023) (2) |
| Nov 6, 2023 | 3 | [SEALED] Complaint filed against Scilex Holding Company, Scilex Pharmaceuticals Inc. (Filing fee $ 402, receipt number ADEDC-4266719) - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Exhibits A-K, # 2 Exhibit L, # 3 Civil Cover Sheet)(jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023) (0) |
| Nov 6, 2023 | 2 | DECLARATION of Thatcher A. Rahmeier re 1 MOTION for Confidential Treatment of the Complaint and its Exhibit L, by Takeda Pharmaceuticals U.S.A., Inc. (jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023) (2) |
| Nov 6, 2023 | 1 | MOTION for Confidential Treatment of the Complaint and its Exhibit L - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Proposed Order)(jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023) (0) |
